Endo International has announced it acquired the rights to Natesto, a testosterone nasal gel that acts as replacement therapy in men diagnosed with hypogonadism, from Trimel BioPharma SRL. Natesto, approved by the U.S. Food and Drug Administration (FDA) earlier this year, is an androgen that can be used as a therapy for patients suffering from a deficit or absence of endogenous testosterone, such as congenital or acquired hypogonadism and/or congenital or acquired hypogonadotropic hypogonadism, two conditions in which there is a decrease in either or both of the two major functions of the testes: sperm production and/or testosterone production. These abnormalities can result from disease of the testes or disease of the pituitary or hypothalamus. In previous studies, a link between prostate cancer and hypogonadism was found. For example, in a study published in the Urology journal, researchers observed that prostate cancer was present in more than 1 of 7 hypogonadal men with levels of prostate specific antigen (PSA) of 4.0 ng/mL or less. Overall they found that severe reductions in testostero